Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Beats Expectations By $0.21 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21, FiscalAI reports. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) EPS.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• AMVUTTRA delivered record growth, with TTR revenue reaching $1.03 billion and total net product revenue rising 74% year over year to approximately $1.2 billion in Q2. AMVUTTRA revenue exceeded $1 billion for the first time, implying an annualized run rate above $4 billion.
• Alnylam lowered 2026 TTR revenue guidance by $200 million at the midpoint to $4.2 billion-$4.5 billion, citing normalization of pent-up second-line demand after the initial launch. Total net product revenue guidance is now $4.7 billion-$5.1 billion.
• Management emphasized strong long-term commercial fundamentals, including approximately 80% of new treatment starts coming from the first-line setting, more than 90% adherence, broad reimbursement access, and over 1,700 new prescribers added since the ATTR-CM launch. The company also sees potential benefit from the expected mid-2031 U.S. generic entry for tafamidis and AstraZeneca’s unsuccessful CARDIO-TTRansform study.
• The company announced a collaboration with BeOne to commercialize and distribute AMVUTTRA in mainland China and Macau, subject to regulatory approval. Alnylam is also expanding AI partnerships focused on drug discovery, disease identification, and earlier ATTR-CM diagnosis.
• Alnylam maintained confidence in the ongoing TRITON-CM study of nucresiran despite the competing eplontersen trial failure, citing differences in molecule characteristics, study design, and prior RNAi data. Management may adjust enrollment or the statistical analysis plan after reviewing the full competitor data, while several pipeline readouts are expected in the second half of 2026.

Alnylam Pharmaceuticals Stock Down 29.1%

Alnylam Pharmaceuticals stock traded down $83.37 during mid-day trading on Thursday, reaching $203.25. The company’s stock had a trading volume of 6,433,743 shares, compared to its average volume of 1,335,165. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals has a 12 month low of $199.88 and a 12 month high of $495.55. The business’s 50 day simple moving average is $291.70 and its 200 day simple moving average is $313.42. The company has a market capitalization of $27.14 billion, a price-to-earnings ratio of 55.53 and a beta of 0.27.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $243,000. Horizon Investments LLC lifted its stake in Alnylam Pharmaceuticals by 18.5% in the third quarter. Horizon Investments LLC now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 63 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 35.1% in the 3rd quarter. Larson Financial Group LLC now owns 300 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 78 shares during the period. Greenline Wealth Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $96,000. Finally, Summit Securities Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $80,000. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the subject of a number of research reports. HC Wainwright increased their target price on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. reduced their price target on shares of Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Bank of America dropped their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research report on Friday, July 10th. Finally, Truist Financial lowered their target price on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $452.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.